Meningioma Patient Survey Results to be Presented at American Brain Tumor Association Annual Conference

Printer Friendly

July 21, 2016

Tweet This

Long-term impact of meningioma among findings. Register at

The American Brain Tumor Association (ABTA) recently conducted the second in a planned series of surveys aimed at gleaning valuable insights from patients and caregivers about their brain tumor experiences from diagnosis and throughout the trajectory of the disease. The ABTA’s first survey in 2015 elicited responses from more than 2,300 patients and caregivers representing all tumor types. This most recent effort focused specifically on the meningioma patient population.

Meningiomas, which represent about 34 percent of all primary brain tumors, are typically slow growing and frequently benign. However, depending on the tumor size, location and treatment, patients can develop debilitating, lingering, and potentially life-threatening side effects.

Preliminary findings from more than 1,800 respondents were presented at the 2016 Society for Neuro-Oncology (SNO) International Meeting on Meningioma in June. Gelareh Zadeh, MD, PhD, FRCS(C), FAANS, Toronto Western Hospital, University Health Network, has further analyzed survey responses and will present a full report at the ABTA’s Annual Patient and Family Conference Precision Medicine & its Impact on Brain Tumors: Low Grade, High Grade & Metastatic on July 29-30 in Chicago.  

“Even though meningiomas are the most frequently diagnosed brain tumor, they are severely under-researched and, as a result, not well understood, said Elizabeth Wilson, president and CEO, American Brain Tumor Association. “This survey is an important first step in enhancing our understanding of the meningioma patient experience and encouraging more research and collaborations on efforts to improve the meningioma patient’s treatment options, outcomes, and quality of life.”

Dr. Zadeh will be joined by Nina A. Paleologos, MD, Rush University Medical Center, in a breakout session and discussion of Low Grade Gliomas and Meningiomas.

The ABTA Annual Patient & Family Conference, Precision Medicine and its Impact on Brain Tumors: Low Grade, High Grade and Metastatic, is being held at the Westin O’Hare in Chicago, July 29-30. To register for the conference, go to, call 800-886-ABTA (2282) or email Advance registration is encouraged; limited onsite registration is available.

To view the conference program and register visit, or call 800-886-ABTA (2282) or email


Founded in 1973, the American Brain Tumor Association was the first and is the only national patient advocacy organization committed to funding brain tumor research and providing support and education programs for people of all tumor types and all ages. 

# # #

Media contact: Martha Carlos,, 773-577-8790.